Anti-alk1 antibodies and methods of using the same
AssigneesGenovac Antibody Discovery LLC, Yale University
InventorsHubertus Schleer, William Sessa
Life of this patent
Estimating the term…
Loading patent…
AssigneesGenovac Antibody Discovery LLC, Yale University
InventorsHubertus Schleer, William Sessa
Estimating the term…
The present disclosure provides antibodies that bind to ALK1 and methods/uses of the disclosed antibodies for treating various conditions (e.g., atherosclerosis). The present disclosure provides anti-ALK1 antibodies, comprising the complementarity determining regions (CDRs) of a heavy chain variable sequence and a light chain variable sequence selected from: the heavy chain variable sequence of SEQ ID NO: 2 and the light chain variable sequence of SEQ ID NO: 3. In some embodiments, the disclosed antibodies bind to human ALK1, murine ALK1, cynomolgus ALK1, or a combination thereof. The present disclosure also provides pharmaceutical compositions comprising an anti-ALK1 antibody accordingly to any one of the foregoing aspects or embodiments and a pharmaceutically acceptable carrier.
An anti-ALK1 antibody, comprising the complementarity determining regions (CDRs) of a heavy chain variable sequence and a light chain variable sequence selected from:
An anti-ALK1 antibody comprising a heavy chain comprising a CDRH1 comprising SSYWN (SEQ ID NO:
An anti-ALK1 antibody comprising a heavy chain comprising a CDRH1 comprising SRSYYWG (SEQ ID NO:
Dependencies are inferred from the claim text.